(Formerly known as Central Clinical School)
 |
| What was the impact of the COVID-19 pandemic on people with HIV? Study shows mental health was negatively affected. Image: Unitaid |
The most recent validated publications for the school and departments can be seen on their publications pages, linked to from the headings below. Otherwise, read down the entry for recent notifications. The below is not a comprehensive list.
 |
| Dr Gemma Sharp receiving her Club Melbourne Fellowship award |
Dr Sharp will use this fellowship to attend the International Society for Research on Internet Interventions 11th Scientific Meeting in Pittsburgh US in September 2022 where she will present an evaluation of the world's first positive body image chatbot - a project she has led since 2020. Owing to the success of the chatbot within Australia (over 20,000 users in its first year), the chatbot will be disseminated internationally in late 2022/early 2023.
Pregnancy may have beneficial health effects for women with relapsing-remitting MS in the form of less long-term disability.
Participants are sought for our research project, in which we are seeking to identify the biological mechanisms that underpin this benefit by following Australian women with and without MS over a 3-5 year period. In these women, we will track changes that occur to the immune system before, during, and after pregnancy, and compare these changes against the immune activity in women of the same age who do not have children.
 |
| Blood biomarkers enhance brain injury prognosis: Commentary in The Lancet Neurology. Writeup and image: Medpage Today |
The most recent validated publications for the school and departments can be seen on their publications pages, linked to from the headings below. Otherwise, read down the entry for recent notifications. The below is not a comprehensive list.
 |
| L-R: Muhammad Javaid, Robb Wesselingh and Xianglong Xu |
Muhammad Javaid completed his PhD on 2 August, "Drug-resistant focal cortical dysplasia in epilepsy: insights from cellular models of neuronal development". He was supervised by Professor Patrick Kwan and Dr Ana Antonic-Baker (Department of Neuroscience).
 |
| Professor Christoph Hagemeyer in the lab. His team has received BioCurate Proof of Concept funding for developing a therapy that targets acute thrombosis. |
Professor Christoph Hagemeyer, Head of the NanoBiotechnology Laboratory at Monash University, and his team have received Proof of Concept funding from BioCurate to develop a first-in-class antibody-based therapy that specifically targets acute thrombosis, the cause of many heart attacks, strokes and vascular blockages.
Myocardial infarction and stroke are the two single most common causes of death worldwide due, in part, to limitations with current medicines. Professor Hagemeyer’s team has developed a novel approach to inhibiting thrombosis by “uncoupling” this inhibition from adverse effects such as severe bleeding.
See story on the faculty news feed.
